EA202091016A1 - Пиримидиновое соединение в качестве ингибитора jak киназы - Google Patents

Пиримидиновое соединение в качестве ингибитора jak киназы

Info

Publication number
EA202091016A1
EA202091016A1 EA202091016A EA202091016A EA202091016A1 EA 202091016 A1 EA202091016 A1 EA 202091016A1 EA 202091016 A EA202091016 A EA 202091016A EA 202091016 A EA202091016 A EA 202091016A EA 202091016 A1 EA202091016 A1 EA 202091016A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
kinase inhibitor
jak kinase
pyrimidine compound
methods
Prior art date
Application number
EA202091016A
Other languages
English (en)
Russian (ru)
Inventor
Дженнифер Козак
Райан Хадсон
Гари И.л. Брандт
Роберт Мюррей Маккиннелл
Марта Дэброс
Джерри Нзерем
Original Assignee
ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи filed Critical ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи
Publication of EA202091016A1 publication Critical patent/EA202091016A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Dental Preparations (AREA)
EA202091016A 2017-10-27 2018-10-26 Пиримидиновое соединение в качестве ингибитора jak киназы EA202091016A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577852P 2017-10-27 2017-10-27
PCT/US2018/057682 WO2019084383A1 (en) 2017-10-27 2018-10-26 PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
EA202091016A1 true EA202091016A1 (ru) 2020-07-17

Family

ID=64277858

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091016A EA202091016A1 (ru) 2017-10-27 2018-10-26 Пиримидиновое соединение в качестве ингибитора jak киназы

Country Status (38)

Country Link
US (7) US10308646B2 (enExample)
EP (1) EP3672965B1 (enExample)
JP (1) JP7218364B2 (enExample)
KR (1) KR102613503B1 (enExample)
CN (1) CN111247142B (enExample)
AR (1) AR113803A1 (enExample)
AU (1) AU2018354370B2 (enExample)
BR (1) BR112020008015A2 (enExample)
CA (1) CA3074034A1 (enExample)
CL (1) CL2020001090A1 (enExample)
CR (1) CR20200180A (enExample)
CU (1) CU24671B1 (enExample)
DK (1) DK3672965T3 (enExample)
DO (1) DOP2020000083A (enExample)
EA (1) EA202091016A1 (enExample)
EC (1) ECSP20023795A (enExample)
ES (1) ES2932526T3 (enExample)
GE (2) GEAP202115340A (enExample)
HR (1) HRP20221221T1 (enExample)
HU (1) HUE060401T2 (enExample)
IL (1) IL274037B2 (enExample)
LT (1) LT3672965T (enExample)
MA (1) MA49956B1 (enExample)
MD (1) MD3672965T2 (enExample)
MX (1) MX2020004255A (enExample)
NI (1) NI202000032A (enExample)
PE (1) PE20201495A1 (enExample)
PH (1) PH12020500528A1 (enExample)
PL (1) PL3672965T3 (enExample)
PT (1) PT3672965T (enExample)
RS (1) RS63608B1 (enExample)
SG (1) SG11202001706RA (enExample)
SI (1) SI3672965T1 (enExample)
SM (1) SMT202200409T1 (enExample)
TW (1) TWI789446B (enExample)
UA (1) UA125130C2 (enExample)
WO (1) WO2019084383A1 (enExample)
ZA (1) ZA202001641B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49956B1 (fr) * 2017-10-27 2022-11-30 Theravance Biopharma R&D Ip Llc Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
CN115925705B (zh) * 2018-11-30 2024-12-31 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
JP7470713B2 (ja) * 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
JP7482152B2 (ja) * 2019-04-24 2024-05-13 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー 皮膚疾患の処置のためのピリミジンjak阻害剤 発明の背景
BR112023001283A2 (pt) * 2020-07-28 2023-02-14 Arcutis Biotherapeutics Inc Composição farmacêutica tópica; método para tratar uma doença, distúrbio ou afecção inflamatória de pele em um indivíduo que necessita do mesmo; e método para intensificar a penetração em pele em um indivíduo de uma formulação farmacêutica tópica
JP2023543670A (ja) * 2020-08-26 2023-10-18 ナロ・セラピューティクス Mycファミリー癌原遺伝子タンパク質のモジュレーター
WO2022076771A1 (en) * 2020-10-08 2022-04-14 Icahn School Of Medicine At Mount Sinai Compositions for treatment alopecia areata, biomarkers for treatment success, and methods of use thereof
JP2024516299A (ja) * 2021-05-03 2024-04-12 インサイト・コーポレイション 結節性痒疹の治療のためのルキソリチニブ
TW202311256A (zh) * 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療fxr誘發之搔癢之il-31調節劑
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
EP4447930A1 (en) 2021-12-15 2024-10-23 Arcutis Biotherapeutics, Inc. Stable formulations of shr0302
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
CN115487301B (zh) * 2022-11-08 2023-07-07 四川大学华西医院 Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
JP2008525422A (ja) 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
ATE508126T1 (de) 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
TW200817391A (en) 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
AU2007269540B2 (en) 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
RU2014129740A (ru) 2011-12-22 2016-02-10 Ф.Хоффманн-Ля Рош Аг Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (enExample) 2014-08-21 2018-03-31
JP2017535520A (ja) * 2014-09-30 2017-11-30 ハンミ・ファイン・ケミカル・カンパニー・リミテッドHanmi Fine Chemical Co., Ltd. 高純度の(r)−9−[2−(ホスホノメトキシ)プロピル]アデニンの製造方法
ES2924698T3 (es) 2015-05-28 2022-10-10 Theravance Biopharma R&D Ip Llc Proceso e intermedios para la preparación de compuestos de naftiridina como inhibidores de quinasa JAK
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
WO2017189822A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
MA49956B1 (fr) 2017-10-27 2022-11-30 Theravance Biopharma R&D Ip Llc Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
JP7482152B2 (ja) 2019-04-24 2024-05-13 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー 皮膚疾患の処置のためのピリミジンjak阻害剤 発明の背景
JP7470713B2 (ja) 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物

Also Published As

Publication number Publication date
KR20200078517A (ko) 2020-07-01
RS63608B1 (sr) 2022-10-31
SMT202200409T1 (it) 2022-11-18
US10308646B2 (en) 2019-06-04
EP3672965B1 (en) 2022-09-07
US20190241555A1 (en) 2019-08-08
IL274037A (en) 2020-06-30
US10988470B2 (en) 2021-04-27
PH12020500528A1 (en) 2021-06-07
JP7218364B2 (ja) 2023-02-06
JP2021501151A (ja) 2021-01-14
ECSP20023795A (es) 2020-06-30
SG11202001706RA (en) 2020-03-30
EP3672965A1 (en) 2020-07-01
PL3672965T3 (pl) 2023-01-16
DK3672965T3 (da) 2022-10-03
US20190127364A1 (en) 2019-05-02
HRP20221221T1 (hr) 2022-12-09
HUE060401T2 (hu) 2023-02-28
TWI789446B (zh) 2023-01-11
MX2020004255A (es) 2020-07-29
BR112020008015A2 (pt) 2020-10-27
MA49956B1 (fr) 2022-11-30
TW201930304A (zh) 2019-08-01
AU2018354370B2 (en) 2023-04-27
US20210214349A1 (en) 2021-07-15
IL274037B2 (en) 2023-11-01
PT3672965T (pt) 2022-09-29
KR102613503B1 (ko) 2023-12-13
GEP20227344B (en) 2022-01-25
CR20200180A (es) 2020-08-12
US20200140430A1 (en) 2020-05-07
GEAP202115340A (en) 2021-08-10
US20200369660A1 (en) 2020-11-26
US11814377B2 (en) 2023-11-14
PE20201495A1 (es) 2020-12-29
CA3074034A1 (en) 2019-05-02
ZA202001641B (en) 2021-04-28
AU2018354370A1 (en) 2020-04-09
US10774080B2 (en) 2020-09-15
MA49956A (fr) 2020-07-01
LT3672965T (lt) 2022-10-10
US20240158389A1 (en) 2024-05-16
US12172994B2 (en) 2024-12-24
UA125130C2 (uk) 2022-01-12
MD3672965T2 (ro) 2022-12-31
ES2932526T3 (es) 2023-01-20
CL2020001090A1 (es) 2020-08-21
CU24671B1 (es) 2023-07-12
CN111247142B (zh) 2022-12-02
SI3672965T1 (sl) 2022-11-30
NI202000032A (es) 2020-10-09
CN111247142A (zh) 2020-06-05
AR113803A1 (es) 2020-06-10
US10562894B2 (en) 2020-02-18
US20220396573A1 (en) 2022-12-15
DOP2020000083A (es) 2020-08-15
CU20200053A7 (es) 2021-03-11
WO2019084383A1 (en) 2019-05-02
US11420965B2 (en) 2022-08-23
IL274037B1 (en) 2023-07-01

Similar Documents

Publication Publication Date Title
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
PH12020500528A1 (en) Pyrimidine compound as jak kinase inhibitor
EA201891091A1 (ru) Соединения ингибитора jak киназы для лечения респираторного заболевания
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
EA201691302A1 (ru) Новые гетероциклические соединения
EA201690752A1 (ru) Ингибиторы g12c kras
EA201600636A1 (ru) 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
JOP20170164A1 (ar) مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري
EA202192822A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
EA201990656A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7